Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo.
about
X-Ray Psoralen Activated Cancer Therapy (X-PACT)Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapyAnti-HER2 vaccines: new prospects for breast cancer therapyClinical significance of pAkt and pErk1/2 expression in early-stage breast cancer patients treated with anthracycline-based adjuvant chemotherapy.Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected].Improving Multi-Epitope Long Peptide Vaccine Potency by Using a Strategy that Enhances CD4+ T Help in BALB/c Mice.Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells.Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment.Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccinesPolyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers
P2860
Q28553818-94F61A7E-58E0-4C87-8192-83C049EC95D0Q33828409-2B46D16E-406E-4394-8238-1ACDC992FE78Q34105959-4846AB25-5D04-48EF-A2CC-73CE848A764AQ35167772-64AE416B-DCED-444A-97DA-1EAB3CE61E3BQ35836070-B2626671-0070-464B-A612-50517910227AQ35838039-236FF2A7-27CC-468F-8172-DA98FA4314FCQ36245418-87149184-5233-4485-A7FD-77924CC5CDC1Q37123849-70421FC7-ABD6-4D62-9536-2B53E9252212Q37173925-ECC91ECC-B8F8-4026-9CC5-33F1A4CAF71DQ58793646-23FA3F87-8358-4F24-AF74-E63EB442FD5C
P2860
Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo.
@ast
Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo.
@en
type
label
Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo.
@ast
Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo.
@en
prefLabel
Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo.
@ast
Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo.
@en
P2093
P2860
P356
P1476
Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo
@en
P2093
Amy C Hobeika
Andrea Amalfitano
Gangjun Lei
Gayathri R Devi
Haixiang Jiang
Junping Wei
Michael A Morse
Neil Spector
Sharon Peplinski
Takuya Osada
P2860
P304
P356
10.1002/IJC.24995
P577
2010-06-01T00:00:00Z